TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25145469
Drug: Insulin initiation
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin initiation support program
Study: 25145775
Drug: Control (Japanese
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (Japanese Encephalitis vaccine)
Study: 25148882
Drug: Prenatal glucocorticoid
Normalized name: Ardisia crenata root extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prenatal glucocorticoid treatment
Study: 25149088
Drug: MEDI-575 (3,
Approvals — FDA: no, EMA: no, PMDA: no
Description: MEDI-575 (3, 6, 9, 12, or 15 mg/kg) once weekly (QW)
Study: 25149088
Drug: MEDI-575 (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: MEDI-575 (25 or 35 mg/kg) every 3 weeks (Q3W)
Study: 25150798
Drug: Ibrutinib 420
Normalized name: ibrutinib 420 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibrutinib 420 mg once daily plus rituximab 375 mg/m² intravenously (IV) weekly during cycle 1, then once per cycle until cycle 6, followed by continuous daily single-agent ibrutinib 420 mg until disease progression or until toxicities or complications precluded further treatment.
Study: 25155588
Drug: GS-9669 100
Normalized name: GS-100
DrugBank: GS-100 (DB18337)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GS-9669 100 mg BID
Study: 25155588
Drug: GS-9669 500
Approvals — FDA: no, EMA: no, PMDA: no
Description: GS-9669 500 mg QD
Study: 25155588
Drug: GS-9669 500
Approvals — FDA: no, EMA: no, PMDA: no
Description: GS-9669 500 mg BID
Study: 25155604
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg DTG once daily for 5 days
Study: 25155604
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg DTG once daily in combination with 700/100 mg FPV-RTV every 12 h for 10 days
Study: 25156560
Drug: tetanus-diphtheria-acellular pertussis
Normalized name: acellular pertussis vaccine, inactivated / diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated
Approvals — FDA: no, EMA: no, PMDA: no
Description: tetanus-diphtheria-acellular pertussis vaccine
Study: 25157214
Drug: Sugammadex 4.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugammadex 4.0 mg/kg administered at least 15 min after the last dose of rocuronium
Study: 25162465
Drug: sEH inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: sEH inhibitor (sEHI)
Study: 25163595
Drug: Neoadjuvant IMRT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant IMRT (median dose 50 Gy, 26-55) followed by surgery and IOERT (10-12 Gy)
Study: 25164021
Drug: PDC31 (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: PDC31 (1 mg/kg/h)
Study: 25164021
Drug: PDC31 (0.01,
Approvals — FDA: no, EMA: no, PMDA: no
Description: PDC31 (0.01, 0.05, 0.15, 0.3, 0.5, 1 mg/kg/h)
Study: 25164234
Drug: Docetaxel 100
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel 100 mg/m(2) intravenously on day 1, and irinotecan 80 mg/m(2) on days 1 and 8, of a 21-day cycle up to 15 cycles or until disease progressed.
Study: 25164234
Drug: Docetaxel and
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel and irinotecan combination treatment.
Study: 25164945
Drug: Spironolactone therapy
Normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Spironolactone therapy added to a standard heart failure regimen
Study: 25165428
Drug: Methylnaltrexone administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylnaltrexone administered every other day for up to fourteen days.
Study: 25166023
Drug: Canagliflozin 30,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Canagliflozin 30, 100, 200, or 400 mg once daily or 300 mg twice daily, or placebo
Study: 25166484
Drug: Tramadol hydrochloride
Normalized name: Tramadol Hydrochloride
DrugBank: Tramadol (DB00193)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Tramadol hydrochloride (HCL), 200 to 300 mg/d, twice-daily immediate-release
Study: 25167069
Drug: Intervention: Detoxification
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention: Detoxification treatment for alcohol use disorder
Study: 25167216
Drug: Anti-TNFα therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-TNFα therapy (adalimumab)
Study: 25167216
Drug: Anti-IL-6R therapy
Normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Anti-IL-6R therapy (tocilizumab)
Study: 25169854
Drug: Ketamine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine infusion (0.5 mg/kg over 40 min)
Study: 25170013
Drug: Erlotinib (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erlotinib (150 mg daily) and Dasatinib (70 mg daily)
Study: 25170123
Drug: Imatinib treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imatinib treatment with BCR-ABL1/ABL ≤10% at 3 months
Study: 25170123
Drug: Imatinib treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imatinib treatment with BCR-ABL1/ABL >10% at 3 months
Study: 25170245
Drug: TRAV/TIM-FC (travoprost
Approvals — FDA: no, EMA: no, PMDA: no
Description: TRAV/TIM-FC (travoprost 0.004%/timolol 0.5%) administered once daily at 8 pm for 4-6 weeks
Study: 25171955
Drug: Prescription opioid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prescription opioid users
Study: 25173458
Drug: TACE plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: TACE plus sorafenib (sorafenib at 400 mg/bid, TACE with lipiodol, 50 mg doxorubicin, and PVA particles repeated q6w)
Study: 25174587
Drug: CD33-directed chimeric
Normalized name: DIRECT BLUE 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: CD33-directed chimeric antigen receptor-modified T cells (CART-33)
Study: 25175077
Drug: Caries risk
Normalized name: Tilletia caries
DrugBank: Tilletia caries (DB10705)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caries risk assessment (CRA) decision based on oral hygiene in pediatric patients
Study: 25179634
Drug: sSOAIC (standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: sSOAIC (standard selective ophthalmic artery infusion chemotherapy)
Study: 25179634
Drug: bSOAIC (balloon-assisted
Approvals — FDA: no, EMA: no, PMDA: no
Description: bSOAIC (balloon-assisted selective ophthalmic artery infusion chemotherapy)
Study: 25179634
Drug: Verapamil infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil infusion into the OA and internal carotid artery
Study: 25180155
Drug: Ruxolitinib (JAK1/2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ruxolitinib (JAK1/2 inhibitor)
Study: 25180584
Drug: High-quantity lipid-based
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-quantity lipid-based nutrient supplements (HQ-LNS) with cash (€38/month)
Study: 25180584
Drug: Medium-quantity lipid-based
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medium-quantity lipid-based nutrient supplements (MQ-LNS) with cash (€38/month)
Study: 25180584
Drug: High-quantity lipid-based
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-quantity lipid-based nutrient supplements (HQ-LNS) only
Study: 25181387
Drug: Surgery and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgery and chemotherapy for ovarian cancer
Study: 25182067
Drug: Public health
Normalized name: Healthy Mama
Approvals — FDA: no, EMA: no, PMDA: no
Description: Public health nurse-administered program in Prince Edward Island
Study: 25182067
Drug: Physician-administered program
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physician-administered program in Nova Scotia
Study: 25185097
Drug: TH-302 plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: TH-302 plus doxorubicin induction treatment
Study: 25185097
Drug: TH-302 maintenance
Normalized name: cenobamate
DrugBank: Cenobamate (DB06119)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: TH-302 maintenance therapy
Study: 25185712
Drug: Cyclophosphamide at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclophosphamide at 120 mg/kg plus cyclosporine and prophylaxis
Study: 25185712
Drug: Cyclophosphamide at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclophosphamide at 120 mg/kg
Study: 25186780
Drug: Non-surgical periodontal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-surgical periodontal therapy with adjunctive systemic antibiotics
Study: 25190651
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of AOSLO and OCT
Study: 25191915
Drug: Low-dose buprenorphine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose buprenorphine (0.2-1.6 mg/d, mean dose 0.4 mg/d, mean maximum dose 0.7 mg/d)
Study: 25191939
Drug: C1-esterase inhibitor
Normalized name: HUMAN C1-ESTERASE INHIBITOR
DrugBank: Human C1-esterase inhibitor (DB06404)
Approvals — FDA: no, EMA: no, PMDA: no
Description: C1-esterase inhibitor (C1-inh) administered intravenously at a dose 30-fold greater than that approved for hereditary angioedema (HAE).
Study: 25191939
Drug: C1-esterase inhibitor
Normalized name: HUMAN C1-ESTERASE INHIBITOR
DrugBank: Human C1-esterase inhibitor (DB06404)
Approvals — FDA: no, EMA: no, PMDA: no
Description: C1-esterase inhibitor (C1-inh) at a dose of 2000 units in humans.
Study: 25191939
Drug: C1-esterase inhibitor
Normalized name: HUMAN C1-ESTERASE INHIBITOR
DrugBank: Human C1-esterase inhibitor (DB06404)
Approvals — FDA: no, EMA: no, PMDA: no
Description: C1-esterase inhibitor (C1-inh) combined with polysulfated macromolecules (heparin and dextran sulfate).
Study: 25192745
Drug: Simeprevir (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simeprevir (150 mg once daily) with pegylated interferon alfa-2a/ribavirin (peg-IFN/RBV) for 12 weeks.
Study: 25193617
Drug: Delayed-release mesalamine
Normalized name: mesalamine Delayed Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed-release mesalamine tablets formulated with MMX technology, 8 weeks of treatment for active mild-to-moderate UC.
Study: 25193617
Drug: Delayed-release mesalamine
Normalized name: mesalamine Delayed Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed-release mesalamine tablets formulated with MMX technology, 12 months of maintenance treatment for quiescent UC.
Study: 25197009
Drug: Deferasirox (once
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deferasirox (once daily)
Study: 25198661
Drug: Endostar (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endostar (15 mg/day) combined with gemcitabine (1,000 mg/m(2) on days 1 and 8) and cisplatin (80 mg/m(2) on day 1) for a maximum of four cycles.
Study: 25199919
Drug: Striatal dopamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Striatal dopamine D2-like receptor binding potential (D2BP) measured using positron emission tomography with [(18)F]fallypride
Study: 26704626
Drug: Empagliflozin 25
Normalized name: empagliflozin 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empagliflozin 25 mg single dose
Study: 25200052
Drug: Concurrent valve
Normalized name: VALVE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent valve procedures
Study: 25200593
Drug: Postoperative experience
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postoperative experience as described by patients and caregivers through daily diary entries assessing functional autonomy, postoperative pain, and caregiver burden.
Study: 25200593
Drug: Daily diary
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily diary responses from patients and caregivers regarding their postoperative experience.
Study: 25201125
Drug: DuraSeal polyethylene
Normalized name: polyethylenes
Approvals — FDA: no, EMA: no, PMDA: no
Description: DuraSeal polyethylene glycol (PEG) gel used as a spacer during low-dose rate brachytherapy.
Study: 29905488
Drug: Methylphenidate (MPH)
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylphenidate (MPH) treatment for 8 weeks
Study: 25202139
Drug: Once-weekly bortezomib
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-weekly bortezomib 1.6 mg/m²
Study: 25202139
Drug: Twice-weekly bortezomib
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice-weekly bortezomib 1.3 mg/m²
Study: 25203178
Drug: Pulsed-field gel
Normalized name: Field mushroom
DrugBank: Field mushroom (DB15605)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulsed-field gel electrophoresis (PFGE) analysis
Study: 25203869
Drug: β-D-glucan test
Normalized name: yeast, beta-D-glucan
Approvals — FDA: no, EMA: no, PMDA: no
Description: β-D-glucan test (cut-off 80 pg/ml)
Study: 25203869
Drug: β-D-glucan test
Normalized name: yeast, beta-D-glucan
Approvals — FDA: no, EMA: no, PMDA: no
Description: β-D-glucan test (cut-off 200 pg/ml)
Study: 25208108
Drug: Individualized treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individualized treatment approaches for abdominal pain in IBD patients; specific interventions not detailed.
Study: 25209003
Drug: Multi-omic molecular
Normalized name: Molecular AF
DrugBank: Tolnaftate (DB00525)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Multi-omic molecular profiling (MMP) informed selection of approved cancer treatments
Study: 25209396
Drug: Intravesical sphingomyelin
Normalized name: Valrubicin Intravesical Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravesical sphingomyelin liposomes (4 weekly instillations)
Study: 25209657
Drug: Video capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Video capsule endoscopy (VCE)
Study: 25210104
Drug: Benznidazole (BNZ)
Normalized name: benznidazole
DrugBank: Benznidazole (DB11989)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Benznidazole (BNZ) administered for 30 days, median dose 5.65 mg/kg/day twice daily
Study: 25210104
Drug: Benznidazole (BNZ)
Normalized name: benznidazole
DrugBank: Benznidazole (DB11989)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Benznidazole (BNZ) administered for 30 days
Study: 25210883
Drug: Standard 4-hour
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard 4-hour glucagon stimulation test (GST) with a peak GH cutoff of 3 ng/mL
Study: 25210883
Drug: Standard 4-hour
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard 4-hour glucagon stimulation test (GST) with a peak GH cutoff of 1 ng/mL
Study: 25213183
Drug: Vorinostat maintenance
Normalized name: Vorinostat
DrugBank: Vorinostat (DB02546)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vorinostat maintenance therapy (oral agent) for 21 consecutive days starting day + 60 after autologous transplant, followed by a week off for up to 11 cycles.
Study: 25213183
Drug: Vorinostat maintenance
Normalized name: Vorinostat
DrugBank: Vorinostat (DB02546)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vorinostat maintenance therapy
Study: 25217112
Drug: BIL >1
Approvals — FDA: no, EMA: no, PMDA: no
Description: BIL >1 mg/dl (>17.1 µmol/l) and CHE ≤ 5,900 U/l
Study: 25217734
Drug: Low 25(OH)D
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low 25(OH)D levels (Group 1a, ≤5 ng/mL)
Study: 25217734
Drug: Low 25(OH)D
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low 25(OH)D levels (Group 1b, 5-15 ng/mL)
Study: 25217734
Drug: Normal 25(OH)D
Normalized name: 1α,25(OH)2D3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal 25(OH)D levels (Group 2, >15 ng/mL)
Study: 25219292
Drug: Idursulfase beta
Normalized name: idursulfase beta
DrugBank: Idursulfase beta (DB16190)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Idursulfase beta (0.5mg/kg/week) administered intravenously for 52 weeks
Study: 25220020
Drug: Oral delta-9-tetrahydrocannabinol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral delta-9-tetrahydrocannabinol (THC) treatments
Study: 25220528
Drug: Pulse pressure
Normalized name: dulse extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulse pressure variation (PPV)-guided fluid therapy
Study: 25220574
Drug: High-dose intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose intravenous ascorbic acid (AA) at doses of 5, 30, and 60 g
Study: 25221606
Drug: Vitamin D3
Normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D3 2,000 I.U. daily for 12 weeks
Study: 25222119
Drug: Zidovudine (ZDV)
Normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Zidovudine (ZDV) prophylaxis for PMTCT or triple antiretroviral treatment in pregnancy
Study: 25223394
Drug: Adalimumab (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adalimumab (40 mg) administered subcutaneously every other week
Study: 25223394
Drug: 160 mg
Normalized name: nadolol 160 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 160 mg loading dose of adalimumab
Study: 25224842
Drug: Oral glucose
Normalized name: glucose Oral Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral glucose tolerance testing (OGTT) with 300 ml of glucose-containing fluid
Study: 25224842
Drug: Mixed-meal tolerance
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mixed-meal tolerance testing (MMTT) with 237 ml of fat/protein/carbohydrate-containing fluid
Study: 25225206
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with ACE2 and Ang-(1-7)
Study: 25225420
Drug: Single-agent carfilzomib
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-agent carfilzomib (56 mg/m2)
Study: 25225420
Drug: Carfilzomib plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carfilzomib plus low-dose dexamethasone (45 or 56 mg/m2)
Study: 25225420
Drug: Single-agent carfilzomib
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-agent carfilzomib (70 mg/m2)
Study: 25225420
Drug: Single-agent carfilzomib
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-agent carfilzomib (20 to 56 mg/m2)
Study: 25225420
Drug: Carfilzomib (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carfilzomib (various doses)
Study: 25225437
Drug: Cabozantinib 100
Normalized name: cabozantinib 100 MG Daily Dose Carton
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cabozantinib 100 mg
Study: 25225676
Drug: DNA vaccines
Normalized name: Toxoplasma gondii DNA
Approvals — FDA: no, EMA: no, PMDA: no
Description: DNA vaccines (4 mg administered intramuscularly by Biojector at weeks 0, 4, and 8, with a homologous boost at or after week 32)
Study: 25225676
Drug: DNA vaccines
Normalized name: Toxoplasma gondii DNA
Approvals — FDA: no, EMA: no, PMDA: no
Description: DNA vaccines (4 mg administered intramuscularly by Biojector)
Study: 25225962
Drug: NaviAid G-EYE
Approvals — FDA: no, EMA: no, PMDA: no
Description: NaviAid G-EYE balloon-colonoscope
Study: 25226293
Drug: Exogenous kisspeptin
Normalized name: Kisspeptin
DrugBank: Kisspeptin (DB19112)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exogenous kisspeptin (0.24 nmol/kg) administered intravenously
Study: 25226293
Drug: GnRH (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: GnRH (75 ng/kg) administered intravenously
Study: 25226407
Drug: 20 g
Normalized name: PEG-20 glyceryl oleate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 g ethanol
Study: 25227179
Drug: High saturated
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High saturated fat diet + 3.45 g/d of docosahexaenoic acid (DHA) for 8 weeks
Study: 25230939
Drug: Tdap5 (Adacel)
Normalized name: Adacel
DrugBank: Bordetella pertussis toxoid antigen (formaldehyde, glutaraldehyde inactivated) (DB10991)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tdap5 (Adacel) vaccine administered to 10-year-olds
Study: 25232260
Drug: Anti-mycotic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-mycotic therapy based on the developed algorithm
Study: 25234930
Drug: Cetuximab (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cetuximab (400 mg/m2 at first infusion and 250 mg/m2 subsequently) combined with cisplatin (80 mg/m2, triweekly) and capecitabine (2,000 mg/m2, triweekly for 2 weeks)
Study: 25236503
Drug: 3 Ms
Normalized name: DRESSING,OPTIFOAM NON-ADHES 3X3 MSC1133F
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 Ms (Medication, Meter, and Meals) intervention
Study: 25236916
Drug: IgPro20 (subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: IgPro20 (subcutaneous immunoglobulin)
Study: 25239228
Drug: Sorafenib 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sorafenib 400 mg twice daily after HSCT for 12 cycles (28 days each).
Study: 25239610
Drug: MK-2206 60
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-2206 60 mg QOD
Study: 25239610
Drug: MK-2206 200
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-2206 200 mg QW
Study: 25240453
Drug: On-treatment LDL-C
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: On-treatment LDL-C levels <70 mg/dl
Study: 25240453
Drug: On-treatment LDL-C
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: On-treatment LDL-C levels ≥70 mg/dl
Study: 25241933
Drug: Δ Sequential
Approvals — FDA: no, EMA: no, PMDA: no
Description: Δ Sequential Organ Failure Assessment (SOFA) score measured at ICU admission and after 48 hours
Study: 25242374
Drug: Eribulin mesylate
Normalized name: Eribulin Mesylate
DrugBank: Eribulin (DB08871)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Eribulin mesylate (1.4 mg/m(2)) with trastuzumab (4 mg/kg loading dose followed by 2 mg/kg weekly doses)
Study: 25242374
Drug: Eribulin mesylate
Normalized name: Eribulin Mesylate
DrugBank: Eribulin (DB08871)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Eribulin mesylate (1.4 mg/m(2)) with trastuzumab (8 mg/kg loading dose followed by 6 mg/kg tri-weekly doses)
Study: 25242417
Drug: Intermittent androgen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent androgen deprivation (IAD) with 9 months of leuprolide and flutamide followed by off-treatment interval.
Study: 25245327
Drug: High-dose interleukin-2
Normalized name: Interleukin-2 aldesleukin
DrugBank: Aldesleukin (DB00041)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High-dose interleukin-2 (HD-IL-2) at a dose of 18 MIU/m2/day by continuous IV infusion for 72 hours, repeated every 3 weeks for up to 4 cycles and then every 4 weeks for a further 2 cycles.
Study: 25245327
Drug: Booster radiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Booster radiotherapy (XRT) at 6-12 Gy administered in three daily doses on days -3 to -1 before the first and third cycle of IL-2.
Study: 25245327
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of HD-IL-2 and XRT.
Study: 25245624
Drug: Adalimumab 160
Normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Adalimumab 160 mg at the start, 80 mg 2 weeks later, followed by 40 mg every other week for 52 weeks (with some patients increasing to 80 mg every other week)